Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 781-788

  Jiao, Jin Wen ^a   Fang, Wen ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin resistance; Excision repair cross complementing gene 1; Lung resistance protein; Ovarian cancer; p38 mitogen activated protein kinase; Survivin; Tanshinone IIA

Indexed keywords

CASPASE 3; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE P1; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN; SURVIVIN; TANSHINONE IIA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN COC1; CELL STRAIN DDP; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CISPLATIN; DITERPENES, ABIETANE; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 79551595325     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1107     Document Type: Article

References (43)

1. McClay EF, Albright KD, Jones JA, Eastman A, Christen R and Howell SB: Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 52: 6790-6796, 1992.
2. McClay EF, Albright KD, Jones JA, Christen RD and Howell SB: Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53: 1571-1576, 1993.
3. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
4. Kelland LR: Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs 10: 413-424, 2005.
5. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F and Perego P: Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 3: 21-29, 2003.
6. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
7. Losa JH, Parada Cobo C, Viniegra JG, Sánchez-Arevalo Lobo VJ, Ramón y Cajal S and Sánchez-Prieto R: Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 22: 3998-4006, 2003.
8. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
9. Wang AM, Sha SH, Lesniak W and Schacht J: Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrob Agents Chemother 47: 1836-1841, 2003.
10. Yang LJ, Jeng CJ, Kung HN, Chang CC, Wang AG, Chau GY, Don MJ and Chau YP: Tanshinone IIA isolated from Salvia miltiorrhiza elicits the cell death of human endothelial cells. J Biomed Sci 12: 347-361, 2005.
11. Choi HS, Cho DI, Choi HK, Im SY, Ryu SY and Kim KM: Molecular mechanisms of inhibitory activities of tanshinones on lipopolysaccharide-induced nitric oxide generation in RAW 264.7 cells. Arch Pharm Res 27: 1233-1237, 2004.
12. Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J and Wang W: Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer 116: 799-807, 2005.
13. Yuan SL, Wei YQ, Wang XJ, Xiao F, Li SF and Zhang J: Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J Gastroenterol 10: 2024-2028, 2004.
14. Liu JJ, Zhang Y, Lin DJ and Xiao RZ: Tanshinone IIA inhibits leukemia THP-1 cell growth by induction of apoptosis. Oncol Rep 21: 1075-1081, 2009.
15. Tewari KS and Monk BJ: Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep 7: 419-434 2005.
16. Chan TY: Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharmacother 35: 501-504, 2001.
17. Yokozawa T and Chen CP: Role of Salvia miltiorrhiza radix extract and its compounds in enhancing nitric oxide expression. Phytomedicine 7: 55-61, 2000.
18. Zhou GY, Zhao BL, Hou JW, Ma GE and Xin WJ: Protective effects of sodium tanshinone IIA sulphonate against adriamycin-induced lipid peroxidation in mice hearts in vivo and in vitro. Pharmacol Res 40: 487-491, 1999.
19. Mosaddik MA: In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza bunge against P388 lymphocytic leukemia cells. Phytomedicine 10: 682-685, 2003.
20. Wang Y, Li Q, Fan ZZ, Sun J, Wang YQ, Liu RH and Gao H: Tanshinone IIA induces apoptosis of liver cancer cells via p38MAPK signal transduction. Shi Jie Hua Ren Xiao Hua Za Zhi 17: 124-129, 2009.
21. Bulavin DV and Fornace AJ Jr: p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92: 95-118, 2004.
22. Kuribayashi K and El-Deiry WS: Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol 615: 201-221, 2008.
23. el-Deiry WS, Harper JW, O'Connor PM, VelculescuVE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE and Wang Y: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
24. Chen WJ, Chang CY and Lin JK: Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip)and p21(Cip). Biochem Pharmacol 65: 1777-1785, 2003.
25. Wong SH, Shih RS, Schoene NW and Lei KY: Zinc-induced G2/M blockage is p53 and p21 dependent in normal human bronchial epithelial cells. Am J Physiol Cell Physiol 294: C1342-C1349, 2008.
26. Maxwell SA, Acosta SA and Davis GE: Induction and alternative splicing of the Bax gene mediated byp53 in a transformed endothelial cell line. Apoptosis 4: 109-114, 1999.
27. Martinez-Caballero S, Dejean LM, Jonas EA and Kinnally KW: The role of the mitochondrial apoptosis induced channel MAC in cytochrome c release. J Bioenerg Biomembr 37: 155-164, 2005.
28. Kornmann M, Ishiwata T, Kleeff J, Beger HG and Korc M: Fas and fas-ligand expression in human pancreatic cancer. Ann Surg 231: 368-379, 2000.
29. Morinaga S, Nakamura Y, Ishiwa N, Yoshikawa T, Noguchi Y, Yamamoto Y, Rino Y, Imada T, Takanashi Y, Akaike M, Sugimasa Y and Takemiya S: Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep 12: 1189-1194, 2004.
30. Nakao K, Hamasaki K, Ichikawa T, Arima K, Eguchi K and Ishii N: Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis. Oncol Rep 16: 389-392, 2006.
31. Wang J, Xu Z and Zhang M: Downregulation of survivin expression and elevation of caspase-3 activity involved in pitavastatin-induced HepG 2 cell apoptosis. Oncol Rep 18: 383-387, 2007.
32. Giannetti L, Consolo U, Magnoni C and Lo Muzio L: Apoptosis: escaping strategies in human skin cancer (Review). Oncol Rep 11: 401-405, 2004.
33. Bepler G, Gautam A, McIntyre LM, Beck AF, Chervinsky DS, Kim YC, Pitterle DM and Hyland A: Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol 20: 1353-1360. 2002.
34. Mu D, Hsu DS and Sancar A: Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 271: 8285-8294, 1996.
35. Sancar A: Mechanisms of DNA excision repair. Science 266: 1954-1956, 1994.
36. Zamble DB, Mu D, Reardon JT, Sancar A and Lippard SJ: Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35: 10004-10013, 1996. (Pubitemid 26269915)
37. De Silva IU, McHugh PJ, Clingen PH and Hartley JA: Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 20: 7980-7990, 2000.
38. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NG, Beverloo HB, Hoeijmakers JH and Kanaar R: The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24: 5776-5787, 2004.
39. Sargent RG, Meservy JL, Perkins BD, Kilburn AE, Intody Z, Adair GM, Nairn RS and Wilson JH: Role of the nucleotide excision repair gene ERCC1 in formation of recombination-dependent rearrangements in mammalian cells. Nucleic Acids Res 28: 3771-3778, 2000.
40. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ and Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708, 1994.
41. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F and Reed E: Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20: 645-652, 2000.
42. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC and Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Med 1: 578-582, 1995.
43. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ and Dalton WS: Over expression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87: 2464-2469, 1996.